Dyne Therapeutics, Inc. (DYN): who owns it and who trades it
As of Nov 16, 2026, DYN insiders reported 126 open-market sales worth $169M and 8 purchases worth $315K in the last 12 months, with 77% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jason P Rhodes (Director), with $129M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Dyne Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns DYN
246 funds and institutions reported DYN shares worth $4.4B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is T. Rowe Price Investment Management, Inc. with 21.6%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 30.91M | 21.64% | $687M | +0% |
| BlackRock, Inc. | 12.40M | 8.69% | $276M | +6% |
| Jupiter Topco LLC | 12.00M | 8.40% | $267M | – |
| FMR LLC (Fidelity) | 11.21M | 7.85% | $249M | +26% |
| State Street Corp | 7.46M | 5.22% | $166M | +12% |
| Orbis Allan Gray Ltd | 7.01M | 4.91% | $156M | +4% |
| Atlas Venture Life Science Advisors, LLC | 6.80M | 4.76% | $151M | -26% |
| Vanguard Capital Management LLC | 6.31M | 4.42% | $140M | -1% |
| TCG Crossover Management, LLC | 4.62M | 3.23% | $103M | No change |
| Vanguard Portfolio Management LLC | 4.05M | 2.83% | $89.9M | -3% |
| T. Rowe Price Associates | 3.94M | 2.76% | $87.4M | +69% |
| Fcpm III Services B.v. | 3.85M | 2.69% | $85.5M | -17% |
| Geode Capital Management, LLC | 3.74M | 2.62% | $83.2M | +7% |
| Vestal Point Capital, LP | 3.38M | 2.36% | $75M | -16% |
| Orbimed Advisors LLC | 3.24M | 2.27% | $71.9M | +11% |
| Frazier Life Sciences Management, L.P. | 3.15M | 2.21% | $70M | No change |
| JPMorgan Chase & Co | 3.15M | 2.21% | $67.2M | – |
| Armistice Capital, LLC | 3.09M | 2.16% | $68.6M | -3% |
| California State Teachers Retirement System | 3.00M | 2.10% | $135M | +2049% |
| Perceptive Advisors LLC | 2.69M | 1.88% | $59.7M | -42% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, DYN insiders reported $315K of open-market purchases and $169M of sales. 77% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | John Cox | CEO | Sale plan | 5,513 | $16.82 | $92.7K | Form 4 |
| Nov 13, 2026 | Erick Lucera | CFO | Sale plan | 1,991 | $16.82 | $33.5K | Form 4 |
| Nov 13, 2026 | Douglas Kerr | Head of R&D and CMO | Sale plan | 2,604 | $16.82 | $43.8K | Form 4 |
| Nov 13, 2026 | Johanna Friedl-Naderer | Chief Commercial Officer | Sale plan | 231 | $16.82 | $3.9K | Form 4 |
| Oct 2, 2026 | Brian S Posner | Director | Purchase | 2,500 | $16.00 | $40K | Form 4 |
| Sep 8, 2026 | Johanna Friedl-Naderer | Chief Commercial Officer | Sale | 185 | $18.88 | $3.5K | Form 4 |
| Sep 8, 2026 | Douglas Kerr | Chief Medical Officer | Sale | 1,290 | $18.88 | $24.4K | Form 4 |
| Sep 8, 2026 | John Cox | CEO | Sale | 5,658 | $18.88 | $107K | Form 4 |
| Sep 4, 2026 | Johanna Friedl-Naderer | Chief Commercial Officer | Sale | 900 | $24.35 | $21.9K | Form 4 |
| Sep 4, 2026 | Douglas Kerr | Chief Medical Officer | Sale | 3,745 | $24.35 | $91.2K | Form 4 |
| Aug 14, 2026 | Jason P Rhodes | Director | Sale plan | 1.36M | $25.00 | $34M | Form 4 |
| Aug 14, 2026 | Jason P Rhodes | Director | Sale plan | 478,377 | $25.00 | $12M | Form 4 |
| Aug 14, 2026 | Jason P Rhodes | Director | Sale plan | 322,465 | $25.00 | $8.1M | Form 4 |
| Aug 13, 2026 | Jason P Rhodes | Director | Sale plan | 268,354 | $26.20 | $7M | Form 4 |
| Aug 13, 2026 | Jason P Rhodes | Director | Sale plan | 94,415 | $26.20 | $2.5M | Form 4 |
| Aug 13, 2026 | Jason P Rhodes | Director | Sale plan | 63,643 | $26.20 | $1.7M | Form 4 |
| Aug 13, 2026 | Johanna Friedl-Naderer | Chief Commercial Officer | Sale | 226 | $26.28 | $5.9K | Form 4 |
| Aug 13, 2026 | Douglas Kerr | Chief Medical Officer | Sale | 1,556 | $26.28 | $40.9K | Form 4 |
| Aug 13, 2026 | John Cox | CEO | Sale | 4,986 | $26.28 | $131K | Form 4 |
| Aug 13, 2026 | Erick Lucera | CFO | Sale | 1,797 | $26.28 | $47.2K | Form 4 |
| Jul 27, 2026 | Dirk Kersten | Director | Sale | 5,388 | $26.04 | $140K | Form 4 |
| Jul 27, 2026 | Dirk Kersten | Director | Sale | 256,072 | $25.50 | $6.5M | Form 4 |
| Jul 7, 2026 | Jason P Rhodes | Director | Sale plan | 62,543 | $23.17 | $1.4M | Form 4 |
| Jul 7, 2026 | Jason P Rhodes | Director | Sale plan | 14,844 | $23.62 | $351K | Form 4 |
| Jul 7, 2026 | Jason P Rhodes | Director | Sale plan | 49,193 | $23.17 | $1.1M | Form 4 |
| Jul 7, 2026 | Jason P Rhodes | Director | Sale plan | 11,665 | $23.62 | $276K | Form 4 |
| Jul 7, 2026 | Jason P Rhodes | Director | Sale plan | 29,587 | $23.62 | $699K | Form 4 |
| Jul 7, 2026 | Jason P Rhodes | Director | Sale plan | 124,379 | $23.17 | $2.9M | Form 4 |
| Jul 7, 2026 | Jason P Rhodes | Director | Sale plan | 5,000 | $23.61 | $118K | Form 4 |
| Jul 6, 2026 | Jason P Rhodes | Director | Sale plan | 127,182 | $22.79 | $2.9M | Form 4 |
| Jul 6, 2026 | Jason P Rhodes | Director | Sale plan | 253,039 | $22.79 | $5.8M | Form 4 |
| Jul 6, 2026 | Jason P Rhodes | Director | Sale plan | 100,019 | $22.79 | $2.3M | Form 4 |
| Jun 29, 2026 | Jason P Rhodes | Director | Sale plan | 102,969 | $21.14 | $2.2M | Form 4 |
| Jun 29, 2026 | Jason P Rhodes | Director | Sale plan | 40,702 | $21.14 | $860K | Form 4 |
| Jun 29, 2026 | Jason P Rhodes | Director | Sale plan | 51,756 | $21.14 | $1.1M | Form 4 |
| Jun 26, 2026 | Jason P Rhodes | Director | Sale plan | 162,954 | $21.28 | $3.5M | Form 4 |
| Jun 26, 2026 | Jason P Rhodes | Director | Sale plan | 81,903 | $21.28 | $1.7M | Form 4 |
| Jun 26, 2026 | Jason P Rhodes | Director | Sale plan | 64,411 | $21.28 | $1.4M | Form 4 |
| Jun 25, 2026 | Erick Lucera | CFO | Sale | 2,362 | $20.37 | $48.1K | Form 4 |
| Jun 25, 2026 | Jason P Rhodes | Director | Sale plan | 6,382 | $21.10 | $135K | Form 4 |
| Jun 25, 2026 | Jason P Rhodes | Director | Sale plan | 12,699 | $21.10 | $268K | Form 4 |
| Jun 25, 2026 | Jason P Rhodes | Director | Sale plan | 5,019 | $21.10 | $106K | Form 4 |
| Jun 24, 2026 | Jason P Rhodes | Director | Sale plan | 19,973 | $21.02 | $420K | Form 4 |
| Jun 24, 2026 | Jason P Rhodes | Director | Sale plan | 25,397 | $21.02 | $534K | Form 4 |
| Jun 24, 2026 | Jason P Rhodes | Director | Sale plan | 50,530 | $21.02 | $1.1M | Form 4 |
| Jun 23, 2026 | Jason P Rhodes | Director | Sale plan | 30,774 | $21.13 | $650K | Form 4 |
| Jun 23, 2026 | Jason P Rhodes | Director | Sale plan | 77,855 | $21.13 | $1.6M | Form 4 |
| Jun 23, 2026 | Jason P Rhodes | Director | Sale plan | 39,131 | $21.13 | $827K | Form 4 |
| Jun 23, 2026 | Dirk Kersten | Director | Sale | 1,657 | $21.47 | $35.6K | Form 4 |
| Jun 23, 2026 | Dirk Kersten | Director | Sale | 71,629 | $21.04 | $1.5M | Form 4 |
| Jun 22, 2026 | Dirk Kersten | Director | Sale | 190,676 | $20.57 | $3.9M | Form 4 |
| Jun 18, 2026 | Dirk Kersten | Director | Sale | 46,901 | $20.07 | $941K | Form 4 |
| Jun 17, 2026 | Dirk Kersten | Director | Sale | 37,454 | $20.14 | $754K | Form 4 |
| Jun 16, 2026 | Douglas Kerr | Chief Medical Officer | Sale | 887 | $18.33 | $16.3K | Form 4 |
| Jun 16, 2026 | Johanna Friedl-Naderer | Chief Commercial Officer | Sale | 145 | $18.33 | $2.7K | Form 4 |
| Jun 16, 2026 | John Cox | CEO | Sale | 2,683 | $18.33 | $49.2K | Form 4 |
| Jun 8, 2026 | Brian S Posner | Director | Purchase | 2,000 | $16.94 | $33.9K | Form 4 |
| Jun 3, 2026 | Brian S Posner | Director | Purchase | 2,500 | $17.48 | $43.7K | Form 4 |
| May 26, 2026 | Brian S Posner | Director | Purchase | 2,000 | $18.21 | $36.4K | Form 4 |
| May 20, 2026 | Brian S Posner | Director | Purchase | 2,500 | $17.12 | $42.8K | Form 4 |
| May 13, 2026 | Johanna Friedl-Naderer | Chief Commercial Officer | Sale | 228 | $18.36 | $4.2K | Form 4 |
| May 13, 2026 | Douglas Kerr | Chief Medical Officer | Sale | 1,564 | $18.36 | $28.7K | Form 4 |
| May 13, 2026 | Erick Lucera | CFO | Sale | 1,448 | $18.36 | $26.6K | Form 4 |
| May 13, 2026 | John Cox | CEO | Sale | 3,311 | $18.36 | $60.8K | Form 4 |
| May 6, 2026 | Jason P Rhodes | Director | Sale plan | 21,926 | $18.18 | $399K | Form 4 |
| May 6, 2026 | Jason P Rhodes | Director | Sale plan | 43,621 | $18.18 | $793K | Form 4 |
| May 6, 2026 | Jason P Rhodes | Director | Sale plan | 428 | $18.18 | $7.8K | Form 4 |
| May 6, 2026 | Jason P Rhodes | Director | Sale plan | 17,244 | $18.18 | $313K | Form 4 |
| May 5, 2026 | Jason P Rhodes | Director | Sale plan | 3,056 | $18.03 | $55.1K | Form 4 |
| May 5, 2026 | Jason P Rhodes | Director | Sale plan | 6,081 | $18.03 | $110K | Form 4 |
| May 5, 2026 | Jason P Rhodes | Director | Sale plan | 60 | $18.03 | $1.1K | Form 4 |
| May 5, 2026 | Jason P Rhodes | Director | Sale plan | 2,403 | $18.03 | $43.3K | Form 4 |
| May 4, 2026 | Jason P Rhodes | Director | Sale plan | 61 | $18.00 | $1.1K | Form 4 |
| May 4, 2026 | Jason P Rhodes | Director | Sale plan | 2,466 | $18.00 | $44.4K | Form 4 |
| May 4, 2026 | Jason P Rhodes | Director | Sale plan | 3,136 | $18.00 | $56.4K | Form 4 |
| May 4, 2026 | Jason P Rhodes | Director | Sale plan | 6,241 | $18.00 | $112K | Form 4 |
| Apr 28, 2026 | Jason P Rhodes | Director | Sale plan | 26 | $19.00 | $494 | Form 4 |
| Apr 28, 2026 | Jason P Rhodes | Director | Sale plan | 52 | $19.00 | $988 | Form 4 |
| Apr 28, 2026 | Jason P Rhodes | Director | Sale plan | 1 | $19.00 | $19 | Form 4 |
| Apr 28, 2026 | Jason P Rhodes | Director | Sale plan | 47,082 | $18.38 | $865K | Form 4 |
| Apr 28, 2026 | Jason P Rhodes | Director | Sale plan | 1,170 | $18.38 | $21.5K | Form 4 |
| Apr 28, 2026 | Jason P Rhodes | Director | Sale plan | 21 | $19.00 | $399 | Form 4 |
| Apr 28, 2026 | Jason P Rhodes | Director | Sale plan | 59,870 | $18.38 | $1.1M | Form 4 |
| Apr 28, 2026 | Jason P Rhodes | Director | Sale plan | 119,115 | $18.38 | $2.2M | Form 4 |
| Apr 27, 2026 | Jason P Rhodes | Director | Sale plan | 45,709 | $18.15 | $830K | Form 4 |
| Apr 27, 2026 | Jason P Rhodes | Director | Sale plan | 90,943 | $18.15 | $1.7M | Form 4 |
| Apr 27, 2026 | Jason P Rhodes | Director | Sale plan | 35,947 | $18.15 | $652K | Form 4 |
| Apr 27, 2026 | Jason P Rhodes | Director | Sale plan | 894 | $18.15 | $16.2K | Form 4 |
| Apr 24, 2026 | Jason P Rhodes | Director | Sale plan | 72,310 | $18.48 | $1.3M | Form 4 |
| Apr 24, 2026 | Jason P Rhodes | Director | Sale plan | 710 | $18.48 | $13.1K | Form 4 |
| Apr 24, 2026 | Jason P Rhodes | Director | Sale plan | 28,583 | $18.48 | $528K | Form 4 |
| Apr 24, 2026 | Jason P Rhodes | Director | Sale plan | 36,345 | $18.48 | $672K | Form 4 |
| Apr 23, 2026 | Jason P Rhodes | Director | Sale plan | 15,148 | $19.19 | $291K | Form 4 |
| Apr 23, 2026 | Jason P Rhodes | Director | Sale plan | 377 | $19.19 | $7.2K | Form 4 |
| Apr 23, 2026 | Jason P Rhodes | Director | Sale plan | 38,322 | $19.19 | $735K | Form 4 |
| Apr 23, 2026 | Jason P Rhodes | Director | Sale plan | 19,261 | $19.19 | $370K | Form 4 |
| Apr 22, 2026 | Dirk Kersten | Director | Sale | 2,652 | $20.00 | $53K | Form 4 |
| Apr 22, 2026 | Jason P Rhodes | Director | Sale plan | 59,663 | $19.68 | $1.2M | Form 4 |
| Apr 22, 2026 | Jason P Rhodes | Director | Sale plan | 1,485 | $19.68 | $29.2K | Form 4 |
| Apr 22, 2026 | Jason P Rhodes | Director | Sale plan | 150,942 | $19.68 | $3M | Form 4 |
Latest 100 of 134 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jason P Rhodes | Director | – | $129M | Aug 14, 2026 |
| Dirk Kersten | Director | – | $38.6M | Jul 27, 2026 |
| John Cox | CEO & President, Director | – | $536K | Nov 13, 2026 |
| Brian S Posner | Director | $315K | – | Oct 2, 2026 |
| Douglas Kerr | Chief Medical Officer | – | $277K | Nov 13, 2026 |
| Erick Lucera | Chief Financial Officer | – | $262K | Nov 13, 2026 |
| Johanna Friedl-Naderer | Chief Commercial Officer | – | $47.3K | Nov 13, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
DYN short interest
High short interest. 13.0% of DYN shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 16%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 24.38M DYN shares were sold short, 13.0% of the shares outstanding, down 4.3% from the report before. At the average daily volume of 2.26M shares, buying them all back would take about 10.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 24.38M | 13.01% | -4% | 2.26M | 10.8 |
| Oct 15, 2026 | 25.47M | 13.64% | -2% | 3.44M | 7.4 |
| Sep 30, 2026 | 25.98M | 13.91% | +11% | 2.88M | 9.0 |
| Sep 15, 2026 | 23.38M | 12.52% | +12% | 4.28M | 5.5 |
| Aug 31, 2026 | 20.79M | 11.13% | -3% | 1.54M | 13.5 |
| Aug 14, 2026 | 21.46M | 11.49% | -2% | 1.96M | 10.9 |
| Jul 31, 2026 | 21.97M | 11.76% | +2% | 3.06M | 7.2 |
| Jul 15, 2026 | 21.49M | – | -4% | 2.02M | 10.6 |
| Jun 30, 2026 | 22.30M | – | -2% | 2.79M | 8.0 |
| Jun 15, 2026 | 22.81M | – | +2% | 1.59M | 14.3 |
| May 29, 2026 | 22.28M | – | +6% | 1.52M | 14.6 |
| May 15, 2026 | 20.98M | 14.69% | +1% | 1.25M | 16.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Dyne Therapeutics company events
Dyne Therapeutics filed 16 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Sep 29, 2026AnnouncementThe Company issued a press release and presentation announcing additional one-year clinical data from the ACHIEVE trial evaluating z-basivarsen in individuals with DM1. Filing
- Jul 29, 2026ResultsReleased financial results. Filing
- Jul 22, 2026AgreementDyne Therapeutics, Inc. entered into an underwriting agreement with Morgan Stanley & Co. LLC and Jefferies LLC, as representatives of the several underwriters named therein, relating to an underwritten public offering of 18,300,000 shares of the Company’s common stock, par value $0.0001 per share. Filing
- Jul 20, 2026AnnouncementDyne Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted for review its biologics license application for zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) for the treatment of individuals with Duchenne muscular dystrophy amenable to exon 51 skipping. Filing
- Jun 22, 2026LeadershipThe Board of Directors of Dyne Therapeutics, Inc., upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Barry E. Greene as a Class I director to serve on the Board until the Company’s 2027 Annual Meeting of Stockholders and until his successor has been… Filing
- Jun 17, 2026AgreementDyne Therapeutics, Inc. entered into the Second Amendment to its Loan and Security Agreement with Hercules Capital, Inc., in its capacity as administrative agent and collateral agent, and certain other financial institutions party thereto as lenders, dated as of June 27, 2025 (the “Initial Loan… Filing
- Jun 8, 2026VoteReported shareholder vote results. Filing
- Jun 3, 2026AnnouncementThe Company issued a press release announcing full enrollment of the REC of its Phase 1/2 ACHIEVE trial of z-basivarsen in individuals with DM1 with 71 participants. Filing
- May 11, 2026ResultsReleased financial results. Filing
- Mar 2, 2026ResultsReleased financial results. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Dec 23, 2025LeadershipThe Board of Directors of Dyne Therapeutics, Inc., upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Vikram Karnani as a Class II director to serve on the Board until the Company’s 2028 Annual Meeting of Stockholders and until his successor has been… Filing
- Dec 10, 2025AgreementDyne Therapeutics, Inc. entered into an underwriting agreement with Morgan Stanley & Co. LLC, Jefferies LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as representatives of the several underwriters named therein, relating to an underwritten public offering of… Filing
- Dec 8, 2025DebtTook on new debt. Filing
- Dec 8, 2025AnnouncementThe Company issued a press release announcing positive topline results from the REC of its DELIVER trial evaluating z-rostudirsen in individuals with DMD amenable to exon 51 skipping. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Dyne Therapeutics financials
Famous investors that hold DYN
5 of the 50 well-known investors we track reported holding DYN in their latest 13F filing. The largest position is Ken Griffin's, worth $31.5M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.95M | $31.5M | 0.0% | +71% |
| Israel Englander · Millennium Management | Q3 2026 | 466,145 | $7.5M | 0.0% | +8% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 259,024 | $4.2M | 0.0% | -13% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 131,700 | $2.1M | 0.0% | -63% |
| George Soros · Soros Fund Management | Q3 2026 | 20,000 | $322K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named DYN in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Wellington Management Group LLP | 13G | 5.7% |
| Nov 16, 2026 | Wellington Management Group LLP | 13G | 5.7% |
Questions about Dyne Therapeutics, Inc. (DYN) stock
Who owns the most DYN stock?
The largest reported owner of Dyne Therapeutics, Inc. (DYN) is T. Rowe Price Investment Management, Inc., with 21.6% of the company. In total, 246 funds and institutions reported holding DYN at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are DYN insiders buying or selling?
In the last 12 months, DYN insiders reported 8 open-market purchases worth $315K and 126 sales worth $169M. The latest trade was on Nov 13, 2026. See every trade.
What is the short interest in DYN?
As of Oct 30, 2026, 24.38M DYN shares were sold short, 13.0% of the shares outstanding, down 4.3% from the report before. At the average daily volume of 2.26M shares, buying them all back would take about 10.8 trading days (days to cover). See the history.
Which famous investors hold DYN?
5 of the 50 well-known investors we track reported DYN in their latest 13F filing, including Ken Griffin, Israel Englander, Ken Fisher. The largest position is worth $31.5M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.